Clinical Trials Logo

Histiocytic Sarcoma clinical trials

View clinical trials related to Histiocytic Sarcoma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03651375 Active, not recruiting - Sarcoma Clinical Trials

Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall

UN-RESARC
Start date: February 11, 2017
Phase: Phase 2
Study type: Interventional

After a screening, which consists of biopsy, physical examination, initial diffusion-weighted magnetic resonance imaging (DWI-MRI), body computed tomography (CT) scan, blood tests and case analysis on Multidisciplinary Team (MDT) meeting, a patient will receive the first course of chemotherapy - doxorubicin 75 mg/sqm and ifosfamide 10 g/sqm (AI regimen) with prophylactic mesna. Then a patient will be irradiated 5x5 Gy and after radiotherapy he or she will receive two courses of AI within 4-6 weeks, depending on the tolerance. Then the response analysis in DWI-MRI and toxicity assessment and will be performed. On the second MDT meeting, a final decision about resectability of the tumor will be made. In case of resectability, a patient will be referred to surgery.

NCT ID: NCT02523040 Active, not recruiting - Clinical trials for Langerhans Cell Histiocytosis (LCH)

A Study of Lenalidomide for Adult Histiocyte Disorders

Start date: August 2015
Phase: Phase 2
Study type: Interventional

This research study is studying a chemotherapy drug Lenalidomide as a possible treatment for one of three histiocyte disorders: Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD), or histiocytic sarcoma (HS).